Epidermal Growth Factor Receptor Mutation Status and the Impact on Clinical Outcomes in Patients with Non-Small Cell Lung Cancer

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1): 7-30. Siegel RL Miller KD Jemal A . Cancer statistics, 2020 . CA Cancer J Clin. 2020 ; 70 ( 1 ): 7 - 30 . Search in Google Scholar

2. Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. 2019; 94(8): 1623-1640. Duma N Santana-Davila R Molina JR . Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment . Mayo Clin Proc. 2019 ; 94 ( 8 ): 1623 - 1640 . Search in Google Scholar

3. Vázquez S, Casal J, Afonso Afonso FJ, Fírvida JL, Santomé L, Barón F, et al. EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10). Cancer Manag Res. 2016; 8(11-20. Vázquez S Casal J Afonso Afonso FJ Fírvida JL Santomé L Barón F EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10) . Cancer Manag Res. 2016 ; 8 : 11 - 20 . Search in Google Scholar

4. Rebuzzi SE, Zullo L, Rossi G, Grassi M, Murianni V, Tagliamento M, et al. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. Int J Mol Sci. 2021; 22(5):. Rebuzzi SE Zullo L Rossi G Grassi M Murianni V Tagliamento M Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer . Int J Mol Sci. 2021 ; 22 ( 5 ):. Search in Google Scholar

5. Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, et al. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012; 13(10): 5177-5182. Qi WX Shen Z Lin F Sun YJ Min DL Tang LN Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis . Asian Pac J Cancer Prev. 2012 ; 13 ( 10 ): 5177 - 5182 . Search in Google Scholar

6. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013; 8(7): 823-859. Lindeman NI Cagle PT Beasley MB Chitale DA Dacic S Giaccone G Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology . J Thorac Oncol. 2013 ; 8 ( 7 ): 823 - 859 . Search in Google Scholar

7. Hanna N, Johnson D, Temin S, Baker S, Brahmer J, Ellis PM, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017; 35(30): 3484-3515. Hanna N Johnson D Temin S Baker S Brahmer J Ellis PM Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update . J Clin Oncol. 2017 ; 35 ( 30 ): 3484 - 3515 . Search in Google Scholar

8. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic revie w and global map by ethnicity (mutMapII). Am J Cancer Res. 2015; 5(9): 2892-2911. Midha A Dearden S McCormack R . EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic revie w and global map by ethnicity (mutMapII) . Am J Cancer Res. 2015 ; 5 ( 9 ): 2892 - 2911 . Search in Google Scholar

9. Lee DH, Srimuninnimit V, Cheng R, Wang X, Orlando M. Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Less ons Learned. Cancer Res Treat. 2015; 47(4): 549-554. Lee DH Srimuninnimit V Cheng R Wang X Orlando M . Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Less ons Learned . Cancer Res Treat. 2015 ; 47 ( 4 ): 549 - 554 . Search in Google Scholar

10. Choi YL, Sun JM, Cho J, Rampal S, Han J, Parasuraman B, et al. EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. Plos One. 2013; 8(2): e56011. Choi YL Sun JM Cho J Rampal S Han J Parasuraman B EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital . Plos One. 2013 ; 8 ( 2 ): e56011 . Search in Google Scholar

11. Szumera-Cie Kiewicz A, Olszewski WT, Tysarowski A, Kowalski DM, G Ogowski M, Krzakowski M, et al. EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. Int J Clin Exp Pathol. 2013; 6(12): 2800-2812. Szumera-Cie Kiewicz A Olszewski WT Tysarowski A Kowalski DM G Ogowski M Krzakowski M EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence . Int J Clin Exp Pathol. 2013 ; 6 ( 12 ): 2800 - 2812 . Search in Google Scholar

12. Syrigos KN, Georgoulias V, Zarogoulidis K, Makrantonakis P, Charpidou A, Christodoulou C. Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study. Anticancer Res. 2018; 38(6): 3735-3744. Syrigos KN Georgoulias V Zarogoulidis K Makrantonakis P Charpidou A Christodoulou C . Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study . Anticancer Res. 2018 ; 38 ( 6 ): 3735 - 3744 . Search in Google Scholar

13. Haghgoo SM, Khosravi A, Mortaz E, Pourabdollah-Toutkaboni M, Seifi S, Sabour S, et al. Prognostic value of rare and complex mutations in EGFR and serum levels of soluble EGFR and its ligan ds in non-small cell lung carcinoma patients. Clin Biochem. 2017; 50(6): 293-300. Haghgoo SM Khosravi A Mortaz E Pourabdollah-Toutkaboni M Seifi S Sabour S Prognostic value of rare and complex mutations in EGFR and serum levels of soluble EGFR and its ligan ds in non-small cell lung carcinoma patients . Clin Biochem. 2017 ; 50 ( 6 ): 293 - 300 . Search in Google Scholar

14. Naderi S, Ghorra C, Haddad F, Kourie HR, Rassy M, El Karak F, et al. EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A si ngle institution experience. Cancer Epidemiol. 2015; 39(6): 1099-1102. Naderi S Ghorra C Haddad F Kourie HR Rassy M El Karak F EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A si ngle institution experience . Cancer Epidemiol. 2015 ; 39 ( 6 ): 1099 - 1102 . Search in Google Scholar

15. Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2013; 8(1): 52-61. Yoshizawa A Sumiyoshi S Sonobe M Kobayashi M Fujimoto M Kawakami F Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients . J Thorac Oncol. 2013 ; 8 ( 1 ): 52 - 61 . Search in Google Scholar

16. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9(2): 154-162. Shi Y Au JS Thongprasert S Srinivasan S Tsai CM Khoa MT A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) . J Thorac Oncol. 2014 ; 9 ( 2 ): 154 - 162 . Search in Google Scholar

17. Yatabe Y, Kerr KM, Utomo A, Rajadurai P, Tran VK, Du X, et al. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. J Thorac Oncol. 2015; 10(3): 438-445. Yatabe Y Kerr KM Utomo A Rajadurai P Tran VK Du X EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey . J Thorac Oncol. 2015 ; 10 ( 3 ): 438 - 445 . Search in Google Scholar

18. Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol. 2012; 7(2): 323-330. Sun PL Seol H Lee HJ Yoo SB Kim H Xu X High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features . J Thorac Oncol. 2012 ; 7 ( 2 ): 323 - 330 . Search in Google Scholar

19. Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH, Zheng MY, et al. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Lung Cancer. 2017; 114(96-102. Tu HY Ke EE Yang JJ Sun YL Yan HH Zheng MY A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer . Lung Cancer. 2017 ; 114 ( 96 - 102 . Search in Google Scholar

20. Jackman DM, Miller VA, Cioffredi LA, Yeap BY, J Nne PA, Riely GJ, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untr eated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009; 15(16): 5267-5273. Jackman DM Miller VA Cioffredi LA Yeap BY J Nne PA Riely GJ Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untr eated non-small cell lung cancer patients: results of an online tumor registry of clinical trials . Clin Cancer Res. 2009 ; 15 ( 16 ): 5267 - 5273 . Search in Google Scholar

21. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361(10): 958-967. Rosell R Moran T Queralt C Porta R Cardenal F Camps C Screening for epidermal growth factor receptor mutations in lung cancer . N Engl J Med. 2009 ; 361 ( 10 ): 958 - 967 . Search in Google Scholar

22. Massarelli E, Johnson FM, Erickson HS, Wistuba II, Papadimitrakopoulou V. Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanism s of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer. 2013; 80(3): 235-241. Massarelli E Johnson FM Erickson HS Wistuba II Papadimitrakopoulou V . Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanism s of EGFR tyrosine kinase inhibitors sensitivity and resistance . Lung Cancer. 2013 ; 80 ( 3 ): 235 - 241 . Search in Google Scholar

23. Esteban E, Majem M, Martinez Aguillo M, Martinez Banaclocha N, Dómine M, Gómez Aldaravi L, et al. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. Cancer Epidemiol. 2015; 39(3): 291-297. Esteban E Majem M Martinez Aguillo M Martinez Banaclocha N Dómine M Gómez Aldaravi L Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study . Cancer Epidemiol. 2015 ; 39 ( 3 ): 291 - 297 . Search in Google Scholar

24. Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicent re observational study by the French ERMETIC-IFCT network. Ann Oncol. 2014; 25(1): 126-131. Beau-Faller M Prim N Ruppert AM Nanni-Metéllus I Lacave R Lacroix L Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicent re observational study by the French ERMETIC-IFCT network . Ann Oncol. 2014 ; 25 ( 1 ): 126 - 131 . Search in Google Scholar

25. Lee B, Lee T, Lee SH, Choi YL, Han J. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers. Oncotarget. 2016; 7(17): 23874-23884. Lee B Lee T Lee SH Choi YL Han J . Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers . Oncotarget. 2016 ; 7 ( 17 ): 23874 - 23884 . Search in Google Scholar

26. Calibasi-Kocal G, Amirfallah A, Sever T, Umit Unal O, Gurel D, Oztop I, et al. EGFR mutation status in a series of Turkish non-small cell lung cancer patients. Biomed Rep. 2020; 13(2): 2. Calibasi-Kocal G Amirfallah A Sever T Umit Unal O Gurel D Oztop I EGFR mutation status in a series of Turkish non-small cell lung cancer patients . Biomed Rep. 2020 ; 13 ( 2 ): 2 . Search in Google Scholar

27. Gahr S, Stoehr R, Geissinger E, Ficker JH, Brueckl WM, Gschwendtner A, et al. EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer. 2013; 109(7): 1821-1828. Gahr S Stoehr R Geissinger E Ficker JH Brueckl WM Gschwendtner A EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice . Br J Cancer. 2013 ; 109 ( 7 ): 1821 - 1828 . Search in Google Scholar

28. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol. 2018; 13(3): 323-358. Lindeman NI Cagle PT Aisner DL Arcila ME Beasley MB Bernicker EH Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology . J Thorac Oncol. 2018 ; 13 ( 3 ): 323 - 358 . Search in Google Scholar